Table 1.

Demographic data and Charlson Comorbidity Score for this cohort of patients. N = number of patients. SD = Standard Deviation

	Total
Age (years), mean (SD)	69.7 (10.32)
Age by decade, N (%)	27,008 (100.0)
20–29	22 (0.1)
30–39	74 (0.3)
40–49	465 (1.7)
50–59	3,659 (13.5)
60–69	9,533 (35.3)
70–79	7,899 (29.2)
80–89	4,987 (18.5)
90–99	369 (1.4)
Gender, N (%)	27,008 (100.0)
Male	26,683 (98.8)
Female	325 (1.2)
Race, N (%)	27,008 (100.0)
White	22,130 (81.9)
Black or African American	2,423 (9.0)
American Indian or Alaska Native	119 (0.4)
Asian	57 (0.2)
Native Hawaiian / Pacific Islander	185 (0.7)
Unknown / Declined	2,094 (7.8)
Ethnicity, N (%)	27,008 (100.0)
Not Hispanic or Latino	24,600 (91.1)
Hispanic or Latino	924 (3.4)
Unknown / Declined	1,484 (5.5)
BMI, mean (SD) [was available for 8,587 patients]	29.1 (5.94)
TURBTs during 5-year follow-up, mean (SD)	0.88 (1.63)
Specific Comorbidities, N (%)
Obesity	3,280 (38.2)
Autoimmune disease	4,297 (15.9)
COPD	9,463 (35.0)
Chronic kidney disease	3,496 (12.9)
Liver cirrhosis	440 (1.6)
Hearing loss	9,528 (35.3)
Hypertension	21,586 (79.9)
Charlson Comorbidity Score, mean (SD)	5 (3.6)
Charlson Comorbidity Indicators, N (%)
Myocardial infarction	4,093 (15.2)
Congestive heart failure	6,893 (25.5)
Peripheral vascular disease	8,676 (32.1)
Cerebrovascular disease	7,053 (26.1)
Dementia	3,230 (12.0)
Chronic pulmonary disease	13,074 (48.4)
Rheumatologic disease	1,199 (4.4)
Peptic ulcer disease	1,933 (7.2)
Diabetes without chronic complications	4,625 (17.1)
Diabetes with chronic complications	6,099 (22.6)
Hemiplegia paraplegia	1,069 (4.0)
Renal disease	8,703 (32.2)
Cancer other than bladder	11,082 (41.0)
Mild liver disease	3,113 (11.5)
Moderate severe liver disease	734 (2.7)
Metastatic solid tumor	3,024 (11.2)
AIDS HIV	126 (0.5)